|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1-2
|
|
pubmed:dateCreated |
1999-6-16
|
|
pubmed:abstractText |
Cladribine is a purine analog with impressive activity in patients with low-grade lymphoproliferative disorders. We studied the combination of cladribine with other antineoplastic drugs against two human-derived B-cell lymphoma cell lines in vitro. Cladribine was combined with cisplatin, daunorubicin, chlorambucil, paclitaxel or etoposide. Under the experimental conditions studied, only the combination of cladribine and cisplatin showed significantly increased cytotoxicity compared to the effect of either drug alone.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1042-8194
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
33
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
141-5
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10194131-Antineoplastic Agents,
pubmed-meshheading:10194131-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10194131-Cell Survival,
pubmed-meshheading:10194131-Chlorambucil,
pubmed-meshheading:10194131-Cisplatin,
pubmed-meshheading:10194131-Cladribine,
pubmed-meshheading:10194131-Drug Screening Assays, Antitumor,
pubmed-meshheading:10194131-Etoposide,
pubmed-meshheading:10194131-Humans,
pubmed-meshheading:10194131-Lymphoma, B-Cell,
pubmed-meshheading:10194131-Paclitaxel,
pubmed-meshheading:10194131-Tumor Cells, Cultured
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Cytotoxicity of 2-chlorodeoxadenosine (cladribine, 2-cdA) in combination with other chemotherapy drugs against two lymphoma cell lines.
|
|
pubmed:affiliation |
Department of Medicine, Long Island Jewish Medical Center campus of the Albert Einstein College of Medicine, New Hyde Park, New York, USA. hoffman@lij.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
